Tocilizumab, an IL6 receptor antagonist approved for systemic sclerosisassociated interstitial lung disease (SScILD), has shown promising results in preserving lung function and reducing M2associated biomarkers in clinical studies (169, 170)
Jun;198(Pt 3):162 73
Stage III (72-96 hours) = Maximal stage of hepatotoxicity = Hepatic failure Clinical features Recurrence of systemic symptoms (anorexia, nausea, vomiting, malaise) Emerging signs & symptoms of hepatic failure : Encephalopathy, jaundice, coagulopathy, hypoglycemia, lactic acidosis, shock
All other authors report no potential conflicts of interest
While there certainly isnt some secret to health, science may have discovered a compound that truly can improve just about every facet of your health